{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:57:48Z","timestamp":1794337068799,"version":"4.9.0"},"reference-count":27,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Donor-derived platelets are used to treat or prevent hemorrhage in patients with thrombocytopenia. However, \u223c5% or more of these patients are complicated with alloimmune platelet transfusion refractoriness (allo-PTR) due to alloantibodies against HLA-I or human platelet antigens (HPA). In these cases, platelets from compatible donors are necessary, but it is difficult to find such donors for patients with rare HLA-I or HPA. To produce platelet products for patients with aplastic anemia with allo-PTR due to rare HPA-1 mismatch in Japan, we developed an ex\u00a0vivo good manufacturing process (GMP)\u2013based production system for an induced pluripotent stem cell\u2013derived platelet product (iPSC-PLTs). Immortalized megakaryocyte progenitor cell lines (imMKCLs) were established from patient iPSCs, and a competent imMKCL clone was selected for the master cell bank (MCB) and confirmed for safety, including negativity of pathogens. From this MCB, iPSC-PLTs were produced using turbulent flow bioreactors and new drugs. In extensive nonclinical studies, iPSC-PLTs were confirmed for quality, safety, and efficacy, including hemostasis in a rabbit model. This report presents a complete system for the GMP-based production of iPSC-PLTs and the required nonclinical studies and thus supports the iPLAT1 study, the first-in-human clinical trial of iPSC-PLTs in a patient with allo-PTR and no compatible donor using the autologous product. It also serves as a comprehensive reference for the development of widely\u00a0applicable allogeneic iPSC-PLTs and other cell products that use iPSC-derived progenitor cells as\u00a0MCB.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008512","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T14:04:30Z","timestamp":1663941870000},"page":"6056-6069","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":44,"title":["Production and nonclinical evaluation of an autologous iPSC\u2013derived platelet product for the iPLAT1 clinical trial"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7271-9175","authenticated-orcid":false,"given":"Naoshi","family":"Sugimoto","sequence":"first","affiliation":[{"name":"1Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5601-9777","authenticated-orcid":false,"given":"Sou","family":"Nakamura","sequence":"additional","affiliation":[{"name":"1Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Shimizu","sequence":"additional","affiliation":[{"name":"1Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Shigemasa","sequence":"additional","affiliation":[{"name":"1Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6704-3633","authenticated-orcid":false,"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuki","family":"Matsuyama","sequence":"additional","affiliation":[{"name":"3Japanese Red Cross Kinki Block Blood Center, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9024-6818","authenticated-orcid":false,"given":"Mitsunobu","family":"Tanaka","sequence":"additional","affiliation":[{"name":"3Japanese Red Cross Kinki Block Blood Center, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1776-0052","authenticated-orcid":false,"given":"Tomoya","family":"Hayashi","sequence":"additional","affiliation":[{"name":"3Japanese Red Cross Kinki Block Blood Center, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3387-1817","authenticated-orcid":false,"given":"Akihiro","family":"Fuchizaki","sequence":"additional","affiliation":[{"name":"3Japanese Red Cross Kinki Block Blood Center, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4835-2545","authenticated-orcid":false,"given":"Masayuki","family":"Nogawa","sequence":"additional","affiliation":[{"name":"4Central Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohide","family":"Watanabe","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6257-4152","authenticated-orcid":false,"given":"Shinichiro","family":"Okamoto","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Handa","sequence":"additional","affiliation":[{"name":"6Center for Transfusion Medicine & Cell Therapy, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Sawaguchi","sequence":"additional","affiliation":[{"name":"7Department of Anatomy, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Momose","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Osaka General Hospital of West Japan Railway Company, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Ryang","family":"Koh","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Osaka General Hospital of West Japan Railway Company, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Tani","sequence":"additional","affiliation":[{"name":"3Japanese Red Cross Kinki Block Blood Center, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7678-4284","authenticated-orcid":false,"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5863-7122","authenticated-orcid":false,"given":"Koji","family":"Eto","sequence":"additional","affiliation":[{"name":"1Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"2023053018335251400_bib1","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1182\/asheducation-2013.1.638","article-title":"Transfusion guidelines: when to transfuse","volume":"2013","author":"Szczepiorkowski","year":"2013","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"issue":"3","key":"2023053018335251400_bib2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/bjh.14423","article-title":"Guidelines for the use of platelet transfusions","volume":"176","author":"Estcourt","year":"2017","journal-title":"Br J Haematol"},{"issue":"3","key":"2023053018335251400_bib3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/bjh.13597","article-title":"Platelet refractoriness--practical approaches and ongoing dilemmas in patient management","volume":"171","author":"Stanworth","year":"2015","journal-title":"Br J Haematol"},{"issue":"4","key":"2023053018335251400_bib4","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"issue":"5","key":"2023053018335251400_bib5","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of pluripotent stem cells from adult human fibroblasts by defined factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"issue":"18","key":"2023053018335251400_bib6","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMra1716145","article-title":"Stem cells in the treatment of disease","volume":"380","author":"Blau","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"5858","key":"2023053018335251400_bib7","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1126\/science.1151526","article-title":"Induced pluripotent stem cell lines derived from human somatic cells","volume":"318","author":"Yu","year":"2007","journal-title":"Science (New York, NY)"},{"issue":"7175","key":"2023053018335251400_bib8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nature06534","article-title":"Reprogramming of human somatic cells to pluripotency with defined factors","volume":"451","author":"Park","year":"2008","journal-title":"Nature"},{"issue":"10","key":"2023053018335251400_bib9","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1182\/blood-2015-08-607929","article-title":"Understanding platelet generation from megakaryocytes: implications for in\u00a0vitro-derived platelets","volume":"127","author":"Sim","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2023053018335251400_bib10","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1007\/s00018-020-03749-8","article-title":"Generation and manipulation of human iPSC-derived platelets","volume":"78","author":"Sugimoto","year":"2021","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"2023053018335251400_bib11","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.stem.2014.01.011","article-title":"Expandable megakaryocyte cell lines enable clinically applicable generation of platelets from human induced pluripotent stem cells","volume":"14","author":"Nakamura","year":"2014","journal-title":"Cell Stem Cell"},{"issue":"7","key":"2023053018335251400_bib12","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/bloodadvances.2016000844","article-title":"Novel TPO receptor agonist TA-316 contributes to platelet biogenesis from human iPS cells","volume":"1","author":"Aihara","year":"2017","journal-title":"Blood Adv"},{"issue":"3","key":"2023053018335251400_bib13","doi-asserted-by":"crossref","first-page":"720","DOI":"10.5966\/sctm.2016-0104","article-title":"Selective inhibition of ADAM17 efficiently mediates glycoprotein ibalpha retention during ex\u00a0vivo generation of human induced pluripotent stem cell-derived platelets","volume":"6","author":"Hirata","year":"2017","journal-title":"Stem Cells Transl Med"},{"issue":"4","key":"2023053018335251400_bib14","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.cell.2018.06.011","article-title":"Turbulence activates platelet biogenesis to enable clinical scale ex vivo production","volume":"174","author":"Ito","year":"2018","journal-title":"Cell"},{"issue":"11","key":"2023053018335251400_bib15","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1111\/trf.15967","article-title":"Frequency of allotype \u201cb\u201d in human platelet antigen 1 to 29 systems among blood donors in Japan estimated using high-resolution melt analysis","volume":"60","author":"Hayashi","year":"2020","journal-title":"Transfusion"},{"issue":"4","key":"2023053018335251400_bib16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1423-0410.2007.00989.x","article-title":"A\u00a0modified rapid monoclonal antibody-specific immobilization of platelet antigen assay for the detection of human platelet antigen (HPA) antibodies: a multicentre evaluation","volume":"93","author":"Campbell","year":"2007","journal-title":"Vox Sang"},{"issue":"8","key":"2023053018335251400_bib17","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1111\/trf.14189","article-title":"Refined methods to evaluate the in\u00a0vivo hemostatic function and viability of transfused human platelets in rabbit models","volume":"57","author":"Watanabe","year":"2017","journal-title":"Transfusion"},{"issue":"11","key":"2023053018335251400_bib18","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.1182\/blood-2007-10-117622","article-title":"Generation of functional platelets from human embryonic stem cells in\u00a0vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors","volume":"111","author":"Takayama","year":"2008","journal-title":"Blood"},{"key":"2023053018335251400_bib19","doi-asserted-by":"crossref","first-page":"102287","DOI":"10.1016\/j.scr.2021.102287","article-title":"Extracellular laminin regulates hematopoietic potential of pluripotent stem cells through integrin beta1-ILK-beta-catenin-JUN axis","volume":"53","author":"Yuzuriha","year":"2021","journal-title":"Stem Cell Res"},{"issue":"2","key":"2023053018335251400_bib20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.transci.2015.05.002","article-title":"Storage of washed platelets in BRS-A platelet additive solutions based on two types of clinically available bicarbonated Ringer's solutions with different electrolyte concentrations","volume":"53","author":"Oikawa","year":"2015","journal-title":"Transfus Apher Sci"},{"issue":"10","key":"2023053018335251400_bib21","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/00006231-198810000-00019","article-title":"Review of platelet labelling and kinetics","volume":"9","author":"Peters","year":"1988","journal-title":"Nucl Med Commun"},{"key":"2023053018335251400_bib22","doi-asserted-by":"crossref","first-page":"11208","DOI":"10.1038\/ncomms11208","article-title":"Large-scale production of megakaryocytes from human pluripotent stem cells by chemically defined forward programming","volume":"7","author":"Moreau","year":"2016","journal-title":"Nat Commun"},{"issue":"13","key":"2023053018335251400_bib23","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1084\/jem.20100844","article-title":"Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells","volume":"207","author":"Takayama","year":"2010","journal-title":"J\u00a0Exp Med"},{"issue":"3","key":"2023053018335251400_bib24","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.stem.2016.06.019","article-title":"Epigenetic variation between human induced pluripotent stem cell lines is an indicator of differentiation capacity","volume":"19","author":"Nishizawa","year":"2016","journal-title":"Cell Stem Cell"},{"issue":"12","key":"2023053018335251400_bib25","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1016\/j.stemcr.2021.11.001","article-title":"Silencing of p53 and CDKN1A establishes sustainable immortalized megakaryocyte progenitor cells from human iPSCs","volume":"16","author":"Sone","year":"2021","journal-title":"Stem Cell Rep"},{"issue":"7648","key":"2023053018335251400_bib26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature21706","article-title":"The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors","volume":"544","author":"Lefrancais","year":"2017","journal-title":"Nature"},{"issue":"23","key":"2023053018335251400_bib27","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1182\/blood-2014-08-593053","article-title":"Comparative analysis of human ex\u00a0vivo-generated platelets vs megakaryocyte-generated platelets in mice: a\u00a0cautionary tale","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/23\/6056\/2054313\/blooda_adv-2022-008512-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/23\/6056\/2054313\/blooda_adv-2022-008512-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T11:28:13Z","timestamp":1701084493000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/23\/6056\/486697\/Production-and-nonclinical-evaluation-of-an"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":27,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2022,12,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008512","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]}}}